Virax Biolabs Group Stock Forecast

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Virax Biolabs Group stock has a target of 3.00, which predicts a 292.16% increase from the current stock price of 0.77.

Price Target: $3.00 (+292.16%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$3.00	$3.00	$3.00
Change	+292.16%	+292.16%	+292.16%	+292.16%

* Price targets were last updated on Mar 31, 2025.

Analyst Ratings

According to 1 stock analyst, the rating for Virax Biolabs Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25
Strong Buy	1	1
Buy	0	0
Hold	0	0
Sell	0	0
Strong Sell	0	0
Total	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $3	Strong Buy	Initiates	$3	+292.16%	Mar 31, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

13.76M

from 6.33K

217,274.82%

from 6.33K

Revenue Next Year

4.08M

from 13.76M

-70.35%

from 13.76M

EPS This Year

0.04

from -1.62

EPS Next Year

n/a

from 0.04

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025	Mar 31, 2026	Mar 31, 2027
Revenue	123.82K	-	8.56K	156.42K	6.33K	13.76M	4.08M
Revenue Growth	23.97%	-	-	1,727.11%	-95.95%	217,274.82%	-70.35%
EPS	-2.71	-1.79	-5.13	-3.36	-1.62	0.04	-
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	18.75	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027
High	14.2M	4.2M
Avg	13.8M	4.1M
Low	13.2M	3.9M

Revenue Growth

Revenue Growth	2026	2027
High	223,671.9%	-69.5%
Avg	217,274.8%	-70.4%
Low	208,745.4%	-71.5%

EPS Forecast

EPS	2026
High	0.04
Avg	0.04
Low	0.04

EPS Growth

EPS Growth	2026
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.